Active, not recruitingPhase 3NCT06194825

EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy

Studying Amyloidosis

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AstraZeneca
Principal Investigator: Shuyang Zhang, MD
Peking Union Medical College
Intervention: Eplontersen(drug)
Enrollment: 64 enrolled
Eligibility: 20-90 years · All sexes
Timeline: 2023 – 2027

Study locations (14)

Research Site, Beijing, China
Research Site, Changsha, China
Research Site, Chengdu, China
Research Site, Chongqing, China
Research Site, Guangzhou, China
Research Site, Hangzhou, China
Research Site, Ha’erbin, China
Research Site, Jinan, China
Research Site, Nanchang, China
Research Site, Shanghai, China
Research Site, Suzhou, China
Research Site, Taiyuan, China
Research Site, Wuhan, China
Research Site, Xi'an, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06194825 on ClinicalTrials.gov

Other trials for Amyloidosis

Additional recruiting or active studies for the same condition.

See all trials for Amyloidosis →

← Back to all trials